All publications

Export 169 results:
Author Title [ Type(Desc)] Year
Conference Proceedings
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2012.  Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Tostevin A, White E, Croxford S, Delpech V, Williams I, Dunn DT, UK HIV Drug Resistance Database.  2015.  Trends in transmitted drug resistance to HIV-1 in the UK since 2010. British HIV Association Conference (BHIVA) 2015.
Chilton DN, Harrison LJ, Green H, Lattimore S, Delpech V, Pillay D.  2008.  Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.
Pillay D, Green H, UK HIV Drug Resistance Database.  2003.  The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.
Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Dunn D, Cohort UKHIVDrug R.  2019.  Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.
Gifford RJM, Pillay D, UK HIV Drug Resistance Database.  2005.  Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, O’Shea S, Tong W, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral genotype in subtype C significantly influences plasma viral load. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.
Journal Article
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Gifford RJM, de Oliveira T, Rambaut A, Myers R.E, Gale C.V, Dunn DT, Shafer R., Vandamme A.M, Kellam P, Pillay D.  2006.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS. 20:1521-9.
Schultze A, Paredes R, Sabin CA, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM et al..  2017.  The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.. Antivir Ther.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin CA, Nelson M, Winston A et al..  2017.  An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J Antimicrob Chemother.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2019.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.. J Virus Erad. 5(4):204-211.
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Collins IJ, Foster C, Tostevin A, Tookey P, Riordan A., Dunn DT, Gibb DM, Judd A.  2017.  Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clin Infect Dis. Epub ahead of print
Le Vu S, Ratmann O, Delpech V, Brown A, Gill NO, Tostevin A, Fraser C, Volz E.  2017.  Comparison of cluster-based and source-attribution methods for estimating transmission risk using large HIV sequence databases.. Epidemics.
Stirrup OT, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2020.  Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Med.
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, O’Shea S, Pillay D, Leigh Brown A.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.